Ask AI

A Call to Action to Overcome Obstacles in the Optimal Testing and Treatment of FLT3-Mutated AML

Achieve a deeper understanding of the biologic rationale for using FLT3 inhibitors in the management of FLT3-mutated acute myeloid leukemia to personalize treatment plans and optimize patient outcomes through certified text modules, an expert-written ClinicalThought commentary, and downloadable slides.

Share

Program Content

Activities

FLT3 in AML
Deciphering FLT3 in AML: Biological Underpinnings, Expression Patterns, and Molecular Profiling
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: July 10, 2025

Expires: January 09, 2026

Activities

FLT3 in AML
Deciphering FLT3 in AML: Biological Underpinnings, Expression Patterns, and Molecular Profiling
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: July 03, 2025

Expires: January 02, 2026

Activities

FLT3-Mutated AML
Expert Perspectives With FLT3-Mutated AML Testing and Treatment: Challenges and Opportunities
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: April 30, 2025

Expires: April 29, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc

Daiichi Sankyo, Inc.